Menopause News and Research

RSS

Menopause is the time in a woman's life when her period stops. It usually occurs naturally, most often after age 45. Menopause happens because the woman's ovary stops producing the hormones estrogen and progesterone.

Scientists identify root cause of chromosomal errors and gene diversity

A team led by a scientist at the University of Pittsburgh School of Medicine has discovered a regulatory protein that influences where genetic material gets swapped between maternal and paternal chromosomes during the process of creating eggs and sperm. The findings, which shed light on the roots of chromosomal errors and gene diversity, appear in tomorrow's issue of Nature.

14 Oct 2010

Stony Brook professor receives 2010 NIH Director's New Innovator Award

Balaji Sitharaman, Ph.D., Assistant Professor of Biomedical Engineering at Stony Brook University, is a 2010 recipient of the National Institutes of Health (NIH) Director's New Innovator Award.

14 Oct 2010

Estrogen therapy may increase risk of kidney stones in postmenopausal women: Study

The use of estrogen therapy by postmenopausal women might increase the risk of developing kidney stones, according to findings by UT Southwestern Medical Center researchers.

12 Oct 2010

BioSante presents update on LibiGel clinical study at NAMS Annual Meeting

BioSante Pharmaceuticals, Inc. presented a LibiGel clinical study update at the 21st Annual Meeting of The North American Menopause Society (NAMS) on October 8, 2010, with more than 1,000 experts and practitioners in menopause and women's health in attendance.

11 Oct 2010

Research-based tip sheets provide details on breast cancer

Throughout October, National Breast Cancer Awareness Month, experts from Fred Hutchinson Cancer Research Center and its clinical care partner, the Seattle Cancer Care Alliance, are offering a series of weekly research-based tip sheets regarding a variety of topics related to breast cancer, including breast cancer prevention, screening and early detection, treatment, and survivorship.

11 Oct 2010

CDC, national leaders issue recommendations to standardize testosterone tests

The use of testosterone assays for patient care and research is on the rise as new research links testosterone to a variety of diseases and conditions. Although the assays are heavily used, discrepancies and inaccuracies in measurements resulting from the various assays are widespread.

11 Oct 2010

Clinical study data on Natural S-equol supplement presented at NAMS Annual Meeting

Four clinical studies that add to the evidence about the use of a new nutritional supplement containing the whole soy germ-based ingredient Natural S-equol to improve health were presented at the North American Menopause Society (NAMS) Annual Meeting.

8 Oct 2010

IMS launches new Recommendations to manage postmenopausal vaginal atrophy

To mark World Menopause Day on 18th October 2010, the International Menopause Society (IMS) is launching new Recommendations for the management of postmenopausal vaginal atrophy, a distressing condition that will affect up to half of women after menopause.

7 Oct 2010

Soy germ-based nutritional supplement helps to manage menopausal symptoms

A new women-s health, whole soy germ-based nutritional supplement containing Natural S-equol reduced the frequency of moderate to severe hot flashes and reduced muscle and joint pain in the first study of its kind among postmenopausal U.S. women, according to peer-reviewed data presented as a poster presentation at the North American Menopause Society (NAMS) Annual Meeting.

7 Oct 2010

BioSante to present LibiGel clinical trial update at NAMS Annual Meeting

BioSante Pharmaceuticals, Inc. today announced that it will present a LibiGel clinical trial update at the 21st Annual Meeting of The North American Menopause Society (NAMS) being held from October 6-9, 2010 at the Sheraton Chicago Hotel & Towers in Chicago, Illinois.

5 Oct 2010

Merck to appeal against jury verdict in retrial of federal FOSAMAX case

Merck & Co., Inc. today said it will appeal a decision by the U.S. District Court for the Southern District of New York that reduced the jury verdict from $8 million to $1.5 million but denied Merck's request for judgment in its favor or a new trial in the case of Boles v. Merck, a retrial of a federal FOSAMAX case.

5 Oct 2010

Fred Hutchinson Center offers research-based tip sheets on breast cancer

4 Oct 2010

Bionovo enters definitive agreement to raise $3.0 million in registered direct offering

Bionovo, Inc., a drug discovery and development company focused on unmet needs in women's health and oncology, today announced that it has entered into definitive agreements to raise approximately $3.0 million in gross proceeds in a registered direct offering through the sale of common stock and warrants.

4 Oct 2010

REMURA Phase 2 clinical study results highlighted at Tear Film & Ocular Surface conference

ISTA Pharmaceuticals, Inc. today highlighted results from the Company's REMURA (bromfenac ophthalmic solution for dry eye) Phase 2 clinical study.

27 Sep 2010

Breast cancer incidence drops, linked to decline in HRT use

A new Canadian study shows that a significant drop in breast cancer incidence among post-menopausal women from 2002 to 2004 coincided with a sharp drop in hormone replacement therapy (HRT) use during the same period. This is the first study to show the link between HRT use and breast cancer among Canadian women.

24 Sep 2010

FDA approves Bionovo's CMC plan for Menerba drug candidate

Bionovo, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted the Company's Chemistry, Manufacturing and Controls (CMC) plan for its lead drug candidate, Menerba, in a Type "B" or "End of Phase 2" meeting.

24 Sep 2010

$Spanish researchers confirm genetic risk factor for osteoporosis and bone fractures$

Spanish researchers confirm genetic risk factor for osteoporosis and bone fractures

Spanish researchers have confirmed there is a genetic risk factor for osteoporosis and bone fractures. Although more studies are still needed, these findings will make it possible to take preventive measures.

22 Sep 2010

ISTA Pharmaceuticals initiates REMURA Phase 3 clinical program for dry eye disease

ISTA Pharmaceuticals, Inc., today announced that it has initiated a Phase 3 clinical program of ISTA's proprietary formulation of REMURA (bromfenac ophthalmic solution for dry eye) for alleviating the signs and symptoms of dry eye disease. The Phase 3 efficacy studies are being conducted under a Special Protocol Assessment (SPA) agreed upon with the U.S. Food and Drug Administration (FDA).

16 Sep 2010

FDA approves Krystexxa drug to treat gout

The U.S. Food and Drug Administration approved Krystexxa (pegloticase) to treat the painful condition known as gout in adults who do not respond to or who cannot tolerate conventional therapy.

15 Sep 2010

Success of assisted reproduction procedures linked to season

The success of an assisted reproduction procedure may depend on the season. This is the finding of new work presented at the World Congress of Fertility and Sterility, in Munich, Germany.

14 Sep 2010